Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Gross Profit: 2014-2024

Historic Gross Profit for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $38.9 million.

  • Cartesian Therapeutics' Gross Profit rose 16.80% to $452,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 97.72%. This contributed to the annual value of $38.9 million for FY2024, which is 49.64% up from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Gross Profit is $38.9 million, which was up 49.64% from $26.0 million recorded in FY2023.
  • Cartesian Therapeutics' 5-year Gross Profit high stood at $110.8 million for FY2022, and its period low was $16.6 million during FY2020.
  • Moreover, its 3-year median value for Gross Profit was $38.9 million (2024), whereas its average is $58.6 million.
  • Its Gross Profit has fluctuated over the past 5 years, first surged by 412.60% in 2021, then slumped by 76.53% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Gross Profit stood at $16.6 million in 2020, then skyrocketed by 412.60% to $85.1 million in 2021, then surged by 30.21% to $110.8 million in 2022, then crashed by 76.53% to $26.0 million in 2023, then spiked by 49.64% to $38.9 million in 2024.